Annual CFF
-$13.14 M
-$52.36 M-133.52%
31 December 2023
Summary:
Cartesian Therapeutics annual cash flow from financing activities is currently -$13.14 million, with the most recent change of -$52.36 million (-133.52%) on 31 December 2023. During the last 3 years, it has fallen by -$27.58 million (-191.09%). RNAC annual CFF is now -112.51% below its all-time high of $105.04 million, reached on 01 December 2019.RNAC Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$124.49 M
+$124.37 M+103645.00%
01 September 2024
Summary:
Cartesian Therapeutics quarterly cash flow from financing activities is currently $124.49 million, with the most recent change of +$124.37 million (+103645.00%) on 01 September 2024. Over the past year, it has increased by +$149.28 million (+602.21%). RNAC quarterly CFF is now at all-time high.RNAC Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$181.73 M
+$149.28 M+460.14%
01 September 2024
Summary:
Cartesian Therapeutics TTM cash flow from financing activities is currently $181.73 million, with the most recent change of +$149.28 million (+460.14%) on 01 September 2024. Over the past year, it has increased by +$208.95 million (+767.47%). RNAC TTM CFF is now at all-time high.RNAC TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAC Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -133.5% | +602.2% | +767.5% |
| 3 y3 years | -191.1% | +8485.8% | +476.0% |
| 5 y5 years | -1985.9% | +2376.0% | +396.7% |
RNAC Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -124.8% | at low | at high | +602.2% | at high | +767.5% |
| 5 y | 5 years | -112.5% | at low | at high | +602.2% | at high | +767.5% |
| alltime | all time | -112.5% | at low | at high | +602.2% | at high | +767.5% |
Cartesian Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $124.49 M(>+9900.0%) | $181.73 M(+460.1%) |
| June 2024 | - | $120.00 K(-99.7%) | $32.44 M(+9.1%) |
| Mar 2024 | - | $43.03 M(+205.6%) | $29.74 M(-326.2%) |
| Dec 2023 | -$13.14 M(-133.5%) | $14.08 M(-156.8%) | -$13.14 M(-51.7%) |
| Sept 2023 | - | -$24.79 M(+858.6%) | -$27.23 M(+1391.8%) |
| June 2023 | - | -$2.59 M(-1835.6%) | -$1.82 M(-104.8%) |
| Mar 2023 | - | $149.00 K(>+9900.0%) | $37.64 M(-4.0%) |
| Dec 2022 | $39.22 M(-25.9%) | - | - |
| Dec 2022 | - | $0.00(-100.0%) | $39.22 M(-35.0%) |
| Sept 2022 | - | $612.00 K(-98.3%) | $60.37 M(-1.4%) |
| June 2022 | - | $36.88 M(+2034.0%) | $61.21 M(+83.7%) |
| Mar 2022 | - | $1.73 M(-91.8%) | $33.32 M(-37.0%) |
| Dec 2021 | $52.90 M(+266.6%) | $21.16 M(+1359.0%) | $52.90 M(+67.7%) |
| Sept 2021 | - | $1.45 M(-83.9%) | $31.55 M(-38.2%) |
| June 2021 | - | $8.98 M(-57.8%) | $51.05 M(+24.2%) |
| Mar 2021 | - | $21.31 M(<-9900.0%) | $41.11 M(+184.9%) |
| Dec 2020 | $14.43 M(-86.3%) | -$190.00 K(-100.9%) | $14.43 M(-82.6%) |
| Sept 2020 | - | $20.95 M(-2288.9%) | $83.16 M(+23.7%) |
| June 2020 | - | -$957.00 K(-82.2%) | $67.23 M(-1.9%) |
| Mar 2020 | - | -$5.37 M(-107.8%) | $68.56 M(-34.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $105.04 M(>+9900.0%) | $68.53 M(+1263.0%) | $105.04 M(+187.1%) |
| Sept 2019 | - | $5.03 M(+1251.6%) | $36.59 M(+15.0%) |
| June 2019 | - | $372.00 K(-98.8%) | $31.81 M(+0.2%) |
| Mar 2019 | - | $31.11 M(>+9900.0%) | $31.75 M(+4455.7%) |
| Dec 2018 | $697.00 K(-98.9%) | $80.00 K(-68.6%) | $697.00 K(-87.7%) |
| Sept 2018 | - | $255.00 K(-18.0%) | $5.66 M(-55.6%) |
| June 2018 | - | $311.00 K(+509.8%) | $12.73 M(-80.8%) |
| Mar 2018 | - | $51.00 K(-99.0%) | $66.37 M(+0.5%) |
| Dec 2017 | $66.02 M(-2.4%) | $5.04 M(-31.3%) | $66.02 M(+3.5%) |
| Sept 2017 | - | $7.33 M(-86.4%) | $63.78 M(+8.5%) |
| June 2017 | - | $53.95 M(<-9900.0%) | $58.80 M(-14.8%) |
| Mar 2017 | - | -$292.00 K(-110.5%) | $69.04 M(+2.0%) |
| Dec 2016 | $67.66 M(+54.1%) | $2.79 M(+18.4%) | $67.66 M(-4.1%) |
| Sept 2016 | - | $2.36 M(-96.3%) | $70.55 M(-29.6%) |
| June 2016 | - | $64.19 M(-3927.4%) | $100.18 M(+136.1%) |
| Mar 2016 | - | -$1.68 M(-129.5%) | $42.44 M(-3.3%) |
| Dec 2015 | $43.91 M(+77.2%) | $5.69 M(-82.2%) | $43.91 M(+14.9%) |
| Sept 2015 | - | $31.98 M(+396.5%) | $38.22 M(+513.0%) |
| June 2015 | - | $6.44 M(-3212.1%) | $6.24 M(-3112.1%) |
| Mar 2015 | - | -$207.00 K | -$207.00 K |
| Dec 2014 | $24.77 M | - | - |
FAQ
- What is Cartesian Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual CFF year-on-year change?
- What is Cartesian Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly CFF year-on-year change?
- What is Cartesian Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Cartesian Therapeutics?
- What is Cartesian Therapeutics TTM CFF year-on-year change?
What is Cartesian Therapeutics annual cash flow from financing activities?
The current annual CFF of RNAC is -$13.14 M
What is the all time high annual CFF for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual cash flow from financing activities is $105.04 M
What is Cartesian Therapeutics annual CFF year-on-year change?
Over the past year, RNAC annual cash flow from financing activities has changed by -$52.36 M (-133.52%)
What is Cartesian Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RNAC is $124.49 M
What is the all time high quarterly CFF for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly cash flow from financing activities is $124.49 M
What is Cartesian Therapeutics quarterly CFF year-on-year change?
Over the past year, RNAC quarterly cash flow from financing activities has changed by +$149.28 M (+602.21%)
What is Cartesian Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RNAC is $181.73 M
What is the all time high TTM CFF for Cartesian Therapeutics?
Cartesian Therapeutics all-time high TTM cash flow from financing activities is $181.73 M
What is Cartesian Therapeutics TTM CFF year-on-year change?
Over the past year, RNAC TTM cash flow from financing activities has changed by +$208.95 M (+767.47%)